ALIGOS THERAPEUTICS ANNOUNCES ACCEPTANCE OF ABSTRACTS ON INCREMENTAL DATA FROM ALG-000184 IN CHB SUBJECTS AND LATE-BREAKER ORAL PRESENTATION OF DATA FROM THE PHASE 2A HERALD STUDY OF ALG-055009 IN MASH SUBJECTS AT THE LIVER MEETING (TLM) 2024

Reuters · 10/15 13:00

Please log in to view news